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Misonidazole protects mouse tumour and normal tissues
from the toxicity of oral CCNU
F.Y.F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
Summary Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out
studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or
in combination with the chemosensitizer misonidazole. In both plasma and KHT tumour the peak
concentration and "early" AUC for total nitrosoureas were about 1.4-1.5 fold greater for the oral compared
to the i.p. route. These differences were reflected in the roughly twofold greater antitumour activity for the
oral route. In contrast, acute toxicity tests showed that oral CCNU was 1.45 times less toxic to normal tissue,
although the dose-limiting organ may be different for the two routes. Misonidazole reduced the antitumour
activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. Similarly, the acute toxicity was also
diminished by a DMF of 0.74. Misonidazole has a complex effect on oral CCNU pharmacokinetics. The
plasma and tumour total nitrosourea peak concentrations were reduced by 1.5 and 1.7 fold respectively.
Misonidazole also reduced the "early" nitrosourea AUC, with the extent of the reduction depending on the
minimum effective concentration (MEC) chosen. For example, the plasma nitrosourea AUC was reduced by
factors of 1.05 and 9.6 for MEC values of 1 and 2pgml-1 respectively. We propose these pharmacokinetic
changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
Clinical trials of such combinations should be accompanied by detailed pharmacokinetic evaluation.
Chemosensitization of tumour response to cytotoxic
agents by the nitroimidazole type of radiosensitizers
is now well established (for review see McNally
1982; Siemann, 1984). A number of clinical
trials of the more promising combinations are
presently in various stages of progress, e.g.
misonidazole (MISO) plus melphalan (Coleman et
al., 1983), benznidazole plus CCNU (Roberts et al.,
1984) and MISO plus CCNU (Siemann, personal
communication). Although the mechanism of
nitroimidazole chemosensitization is still uncertain,
it has become increasingly clear that changes in the
pharmacokinetics of the cytotoxic agents by the
sensitizers can play an important role (Tannock,
1980; Clutterbuck et al., 1982; Hinchliffe et al.,
1983; Workman et al., 1983; Lee & Workman,
1983). The most detailed studies in our laboratory
have been carried out with the combination of
MISO and CCNU in mice. We have shown that
misonidazole reduces the plasma clearance of
CCNU (Lee & Workman, 1983) probably through
inhibition of hepatic drug metabolism (Lee &
Workman, 1984b). This in turn leads to a selective
increase in drug concentration in the tumour
compared to normal tissue by overcoming the lag
in tumour penetration by the active nitrosoureas
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(Lee & Workman, 1984a). We suggested that this
effect of MISO is responsible for both the
enhancement of tumour response and the improved
therapeutic index for the combination as compared
to that for CCNU alone (Lee & Workman, 1984a).
However, in this previous work and in all other
preclinical studies CCNU was given by the i.p.
route, whereas the oral route is invariably used in
the clinic. This unfortunate difference between
experimental and clinical practice is particularly
unsatisfactory since the pharmacokinetics of oral
CCNU are likely to be quite different from those
for other routes of administration because of the
effects of extensive "first-pass" metabolism (Lee et
al., In press). We have therefore investigated the
effect of MISO on the antitumour effect, acute
toxicity and pharmacokinetics of oral CCNU in
mice. The present paper shows that the tumour
and normal tissue toxicity of oral CCNU can
be reduced by MISO. However, despite the
seemingly contrasting effects of misonidazole for
i.p. and oral CCNU, pharmacokinetic studies have
shown them to be both the consequences of
modified CCNU pharmacokinetics.
Materials and methods
Mice, tumour and acute toxicity testing
Adult male C3H/He mice weighing between 25-35 g
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were used in all experiments. The KHT fibro-
sarcoma was grown in the gastrocnemius muscle as
described by Twentyman et al. (1979). Tumour
bearing mice were treated when tumours were
between 200-300mg. The time taken by individual
tumours to reach 4 x their initial size was
calculated and growth delay was the geometric
mean of individual values in a group. Each group
contained 7-9 mice. In acute toxicity studies,
groups of 3-4 mice were treated with various doses
of CCNU and the dose required to cause 50%
lethality at 30 days (LD50/30) was determined by
computerized probit analysis using the Generalized
Linear Interactive Modelling Programme (GLIM)
of the Royal Statistical Society of London.
Drug administration
CCNU was first dissolved in a 1:1 mixture of
ethanol/Cremophor-EL (Sigma). For oral ad-
ministration this was diluted 2:3 with saline so
that mice received 0.005mlg-1. Drug solution was
delivered into the stomach lumen with an oral-
dosing cannula. For i.p. administration the dilution
ratio was 1:4 and mice received at 0.01 m1g-1.
MISO was dissolved in Hanks' balanced salt
solution and injected in 0.04mlg-' i.p., at a dose
500mgkg-1 (2.5mmolkg-1), 0.5h prior to CCNU.
This dose of MISO has no effect on body temper-
ature. Controls received the appropriate vehicles.
Dose modifyingfactors (DMF)
These were calculated from the equation:
DMF=isoeffect dose for CCNU alone/isoeffect
dose for CCNU plus MISO.
A DMF> 1 indicates an enhanced response
(sensitization) while a DMF <1 indicates a reduced
response (protection).
HPLC analysis
The HPLC method for the assay of CCNU and its
metabolites as well as the preparative procedures
for plasma and tumour samples were as described
previously (Lee & Workman, 1983), except that two
columns in series were used instead of one for
better resolution (for details see Lee et al., In
press).
Pharmacokinetic analysis
Area under the concentration-time curve (AUC)
from time 0 to the final time t was estimated by
Simpson's rule. The remaining AUC from t to
infinity (t-oo) was given by Ct/k, where k is the
elimination rate constant estimated by least squares
linear regression analysis and Ct is the
concentration at t. Values of AUCO - are the sums
ofAUCO_, and AUC,_.
Statistics
Statistical analysis was by student's t-test.
Results
Before considering the effects of MISO it may be
useful to illustrate the differences in tumour
response, toxicity and pharmacokinetics for oral
compared to i.p. administered CCNU.
Tumour response and normal tissue toxicity oforal
CCNU: comparison with the i.p. route
Table I shows the results of two experiments
comparing the growth delays in the KHT tumour
for i.p. versus oral CCNU. Oral CCNU was clearly
more active at both doses, with 10mgkg-1 orally
being about as active as twice the dose given i.p.:
that is, the potency was twice as great for the oral
route. In contrast acute lethality tests showed that
oral CCNU was actually less toxic to normal
tissues than i.p. CCNU. The LD50130 values
obtained for pooled data from two experiments
were 45.0 (40.1-53.4)mg/kg-' for the i.p. route
compared to 65.2 (61.5-69.2) for the oral route
(0.01 >P>0.002). This represents a difference of
1.45 fold. Interestingly whereas mice given oral
CCNU died between 9-21 days (median 10 days),
those that received CCNU i.p. died between 4-7
days (median 5 days). This difference in the time of
death is suggestive of a change in the dose-limiting
normal tissue for the two routes of administration.
Table I Comparison of the tumour response of i.p. and
oral CCNU
Dose Route of Growth delay
Experiment (mgkg-1) administration (days) ( s.e.)
10 i.p. 7.8 (6.9-8.8)
10 oral 13.2 (12.2-14.4)
A 20 i.p. 14.7 (14.0-15.6)
20 oral 23.5 (22.1-25.0)
13 i.p. 12.4 (11.3-13.6)
13 oral 20.0 (18.1-22.4)
B 26 i.p. 21.1 (19.2-23.3)
26 oral 24.9 (23.7-26.7)
Plasma and tumour pharmacokinetics oforal
CCNU: comparison with the i.p. route
Orally administered CCNU is rapidly metabolised
to monohydroxylated metabolites during the "first-MISONIDAZOLE REDUCTION OF ORAL CCNU TOXICITY 87
pass" through the gut and the liver. The identities
of these metabolites were found to be exactly the
same as with i.p. CCNU (Lee & Workman, 1983),
namely trans-4-hydroxy CCNU, cis-4-hydroxy
CCNU, cis-3-hydroxy CCNU, trans-3-hydroxy
CCNU and trans-2-hydroxy CCNU. Their relative
proportions were also the same with the cis-4-
hydroxy and particularly the trans-4-hydroxy
CCNU predominant. Only a small amount of
parental CCNU appears systemically after oral
CCNU. The peak plasma CCNU concentration
after an oral dose of 20mgkg-t was 0.46pgml-l
and represents only 5% of the peak concentration
of total nitrosoureas (CCNU plus metabolites).
Following i.p. CCNU, considerably more parent
drug appeared in the plasma: the peak plasma
concentration was approximately 4.0pgml-1, which
represents about 60% of the peak plasma total
nitrosourea concentration (Lee & Workman, 1983).
This is consistent with the idea that i.p. ad-
ministered CCNU is absorbed rapidly, leading to a
breakthrough of parent drug which escapes "first-
pass" metabolism probably by saturating the
microsomal enzymes. On the other hand, oral
CCNU is probably absorbed more slowly; in
consequence the liver metabolising enzymes are able
to metabolize a larger proportion of the parent
drug on its "first-pass".
The second important difference between oral
and i.p. CCNU is that the peak total nitrosourea
concentrations were consistently -1.5 times higher
for the former route, the values for plasma being
8.6pggml- and 5.6pgml-I for oral and i.p. CCNU
respectively (Figure 1). However, at later times the
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Figure 1 Comparison of the plasma total nitro-
soureas pharmacokinetics for oral CCNU (closed
symbols, solid line) and i.p. CCNU (broken line, no
symbols; data from Lee & Workman, 1983) given at
a dose of 20mgkg-1. Different symbols represent
independent experiments. Each point is the mean of 3-
4 mice. Error bars show+s.d.
difference was only minimal. The AUCO_ , for
total nitrosourea was - 1.4 times higher for the
oral route compared to the i.p. route, the values
being 705 and 516pgminml-l respectively. It is
clear too that this increase in AUC was due mainly
to the higher concentrations for the oral route at
early times. A similar difference in peak total
nitrosourea was found in the KHT tumour, the
values being about 6.7 and 4.5pgg-1 for the oral
and i.p. route respectively.
We can now consider the effects of MISO on the
antitumour efficacy and toxicity of oral CCNU and
whether these effects can be explained by modified
pharmacokinetics.
Effect ofMISO on tumour response to oral CCNU
The dose-reponse data for oral CCNU, either alone
or in combination with 500mgkg- MISO, are
shown in Figure 2. It is clear that MISO di-
minished the antitumour activity of CCNU for
doses at or above approximately 7mgkg-1. The
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Figure 2 The effect of MISO (500mgkg-1) on the
dose-response of the KHT sarcoma to oral CCNU.
(-,A) CCNU alone; (0,A) CCNU plus MISO.
Points are geometric means for groups of 7-9 mice.
Error bars show+s.e. Different symbols represent
independent experiments.
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dose modifying factor (DMF, see Methods) varied
from 0.71 at low CCNU doses to 0.59 at high
CCNU doses. It is particularly noteworthy that this
effect of MISO on oral CCNU is the exact opposite
of its effect on i.p. CCNU where it produces an
increase in the antitumour activity, with DMF
values in the range 1.5-1.8 (Siemann, 1981; 1982;
Hirst et al., 1982; Workman & Twentyman, 1982;
Lee & Workman, 1984a).
Effect ofMISO on the acute toxicity oforal CCNU
The protective effect of MISO was similarly demon-
strated for normal tissues. Acute toxicity tests
(Figure 3) showed that MISO increased the LD50130
of oral CCNU from 65.2 (61.5-69.2)mgkg-1
to 88.0 (81.2-95.9)mgkg-1 (0.01 >P>0.002), thus
giving a DMF of 0.74. In contrast, in parallel
experiments the same dose of MISO slightly
reduced the LD50/30 of i.p. CCNU from 45.2 (40.1-
53.4)mgkg-1 to 40.0 (34.3-49.8)mgkg-1, thus
giving a DMF of 1.1 which was not significantly
different from 1 (P>0.05). This DMF for i.p.
CCNU is consistent with previously published
values of 1.0-1.3 (Siemann 1981, 1982; Hirst et al.,
1982).
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Figure 3 The effect of MISO (500mgkg-') on the
acute lethality (LD50/30) or oral CCNU in C3H mice.
(-, A) CCNU alone; (O A\) CCNU plus MISO.
Each point represents a group of 3-4 mice. Different
symbols represent independent experiments. In the
experiment represented by the circles, no deaths
occurred in mice receiving CCNU plus MISO at the
highest dose administered.
Effect ofMISO on the pharmacokinetics oforal
CCNU
Since following oral administration CCNU
concentrations are small when compared with those
of its metabolites, which are themselves at least
equally active (Wheeler et al., 1977), the effect of
MISO on the pharmacokinetics of total nitrosourea
is the most important aspect to consider. These
data are shown in Figure 4. It can be seen that
both plasma and tumour pharmacokinetics were
substantially altered by MISO. When given alone,
peakplasma nitrosourea concentrations were reached
by - 20-30min and post-peak concentrations
declined biphasically. On the other hand, with
MISO treatment the plasma total nitrosourea
concentrations peaked earlier at about 5-10min
and at a lower level, declined rapidly to a plateau
level of 1.4Mgml-1 which persisted for - 6h, and
finally declined at a similar rate as the control. The
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Figure 4 The effect of MISO (500mgkg-1) on the
pharmacokinetics of total nitrosourea in plasma (a)
and KHT tumour (b) after oral CCNU (20mgkg-1).
Closed symbols: CCNU alone; open symbols: CCNU
plus MISO. Different symbols represent independent
experiments. Each point is the mean of 3-4 mice.
Error bars show+s.d.
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nitrosourea concentrations in the tumour generally
reflected those in the plasma (compare Figures 4A
and B).
The effects of MISO on the pharmacokinetic
parameters of total nitrosoureas after oral CCNU
are shown in Table II. To summarize, MISO
reduced the plasma and tumour peak total
nitrosourea concentration by factors of 1.5 and 1.7
respectively. In marked contrast, values for total
nitrosourea AUCOG 0 were reduced only minimally,
by factors of 1.05 and 1.1 for plasma and tumour
respectively. This is because the reduction in AUC
due to the lower and narrower peak was
compensated for by the persistent plateau region of
the elimination profile (Figure 4).
Table II Plasma and KHT tumour pharmacokinetic
parameters of total nitrosourea following i.p. and oral
CCNU (20mgkg-1)
Control MISO
Plasma Tumour Plasma Tumour
Total nitrosourea
AUCO-0o
(pgminml or 705 450 662 410
jugming-)
Total nitrogea
peak concentration
(pgml-' or pgg-1) 8.6 6.7 5.6 3.9
Concentrations of CCNU required to give 1 log
cell kill in vitro are in the range 2-30,jgml-1
(summarized in Lee et al., In press), and Skipper et
al. (1970) claimed that the minimum effective
concentration (MEC) against L1210 cells was
2Mgml-1. Since the monohydroxylated metabolites
of CCNU may be up to twice as toxic as the parent
compound (Wheeler et al., 1977), the nitrosourea
AUC for concentrations 1-2 jgml- 1 might give a
more realistic measure of effective cytotoxic
exposure. Because of its effect on peak
concentration, MISO reduces these values to an
extent which depends on the minimum effective
concentration (MEC) chosen (Table III). It can be
seen that the lower the MEC is set the smaller the
reduction of AUC becomes. For example, the
plasma nitrosourea AUC was reduced by factors of
1.13 and 9.6 for MEC values of 1 and 2pgml-
respectively.
It is significant that with MISO the early peak
(Figure 4) was composed largely of CCNU, the
plasma concentration being 3.1 + 1.2 jgml-1 (s.d.),
which represents 50-60% of the peak total
nitrosoureas, whereas in the controls the value was
0.46+0.05pgml- 1 which was only -~5% of the
peak.
Discussion
Although it has been shown previously that MISO
can protect against the in vitro cytotoxicity of
adriamycin and m-AMSA (West et al., 1981;
Twentyman, 1982), as far as we are aware this
represents the first report of chemoprotection by
MISO in vivo.
We have shown that MISO can clearly have two
directly opposing effects on the activity of CCNU,
depending on the route of administration of the
cytotoxic agent. For i.p. CCNU, MISO has a
sensitizing effect on tumour with little change in
normal tissue response. On the other hand, MISO
is protective when CCNU is given orally. The
degree of protection appears to be similar in
Table III The dependence of the reduction of nitrosourea AUC by MISO on
minimum effective nitrosourea concentration
Plasma AUC Tumour AUC
Minimum effective (4ugminml ) Fold (jigming-1) Fold
concentration reduction reduction
(jgml-1 or pgg-1) Control MISO factor Control MISO factor
00 705 662 1.06 451 410 1.1
0.5 630 588 1.07 423 389 1.09
0.8 618 559 1.11 387 225 1.72
1.0 589 520 1.13 358 55 7.0
1.5 448 320 1.40 321 40 8.0
2.0 460 48 9.6 273 35 7.8
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normal and tumour tissue, with if anything a
slightly greater protection in the tumour. It should
be pointed out that these effects occur at a dose of
MISO (500mgkg-1 or 2.5mmolkg-1) which
causes no change in mouse body temperature.
We previously showed that MISO reduces the
clearance of i.p. CCNU, probably through
inhibition of hepatic drug metabolising enzymes. In
support of this mechanism we have shown that the
same dose of MISO does inhibit drug metabolizing
enzymes in mice (Workman et al., 1983) and more
recently that pharmacological concentrations of
MISO are able to inhibit the hydroxylation of
CCNU by mouse liver microsomes (Lee &
Workman, 1984b). By overcoming the lag in drug
penetration into the tumour this reduced clearance
leads to a selective increase in peak nitrosourea
concentration in the tumour but not in normal
tissue, thus providing a pharmacokinetic
mechanism for chemosensitization and therapeutic
gain (Lee & Workman, 1983; 1984a; 1984b).
Furthermore, detailed studies of the effect of MISO
on tumour and normal tissue CCNU pharmaco-
kinetics suggested that .peak nitrosourea concen-
tration and/or "early" AUC above a minimum
effective concentration are the principle
determinants of cytotoxicity (Lee & Workman,
1984a; Lee et al., In press). The present paper
shows that when CCNU is given orally,
misonidazole reduces the peak nitrosourea
concentration and "early" AUC, but not total
AUC (AUCO a0), both in the plasma and the
tumour, and we propose this to be the underlying
mechanism for the reduction of oral CCNU
cytotoxicity.
Comparing the pharmacokinetic parameters of
oral with i.p. CCNU in the absence of MISO it is
clear that although parent CCNU levels are
actually lower following oral administration, both
the total nitrosourea peak concentration and
"early" AUC in the tumour are greater because of
the higher concentration of metabolites. This
finding explains the comparatively greater tumour
response we have obtained for oral CCNU,
particularly since the metabolites may be more
active than the parent compound (Wheeler et al.,
1977). The difference in peak concentration may be
at least partly due to the fact that absorption is
slower by the oral route and the liver is able to
convert more completely the parent CCNU to
monohydroxylated metabolites. Since these
metabolites are much more hydrophilic than the
parent compound (Wheeler et al., 1977), they are
likely to have lower apparent volumes of
distribution and therefore be present at higher
levels in the plasma. However, penetration into
tumour tissue is clearly not impaired.
In contrast to tumour response we cannot
explain the difference in acute lethal dose between
oral and i.p. CCNU in terms of the altered plasma
pharmacokinetics. At first sight, the higher plasma
exposure might be expected to result in greater
toxicity for the oral route whereas oral CCNU was
in fact - 1.5 times less toxic. However two points
should be borne in mind here. Firstly, deaths from
oral CCNU tended to occur later (median 10 days)
than the normal 4-7 days for i.p. CCNU, possibly
suggesting a change in the dose-limiting organ, e.g.
bone marrow instead of gut. Secondly,
measurements of plasma concentrations will not
necessarily reveal changes in concentrations at
target organs, especially those at the site of uptake.
We have previously found very high nitrosourea
concentrations in the small intestine following i.p.
CCNU (Lee & Workman, 1984a) and it may be
that these are reduced when the drug is given
orally. Further studies using specific assays for gut
and bone marrow damage should allow the
elucidation of the mechanism involved.
The effect of MISO on oral CCNU
pharmacokinetics is very complex. However the
considerably higher peak levels of CCNU in the
presence of MISO is a clear indication that the
drug metabolising process is impaired by the
sensitizer. Rapid distribution of the parent drug
that has escaped "first-pass" metabolism would
then explain the transient nature of the peak. The
persistent plateau region of the total nitrosourea
elimination profile, which immediately follows the
initial peak, is made up almost entirely of the
hydroxylated metabolites. The steady-state situation
suggests that the rate of formation of the
metabolites is equalled by their rate of clearance,
the latter also being slowed by MISO as with the
i.p. route (Lee & Workman, 1983). It is significant
that the clearance of total nitrosoureas returns to
control level by - 6h. In previous experiments
where i.p. CCNU was given at different intervals
following the same dose of MISO we showed that
the duration of pharmacokinetic modification was
also about 6h, and this reflects the time taken for
the circulating MISO to fall below the minimum
effective concentrations of about 100-300pgml-
(Workman, 1980; Lee & Workman, 1983).
Whatever the precise mechanism of these major
changes in pharmacokinetics, it is certain that the
large reduction by MISO in both the plasma and
tumour peak nitrosourea concentrations and
"early" AUC, but not AUCOG 1 is the likely
reason for the apparent reduction of CCNU
cytotoxicity. Furthermore, this lends support to our
proposal that AUCOG0 is comparatively less
important than the other two parameters in
determining the activity of nitrosoureas (Lee &
Workman, 1984a).
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speculating on the possible clinical consequences of
these findings. Not only have we shown here that
the pharmacokinetics are different for the oral
compared to the i.p. route in mice, and that this
results in altered drug efficacy, toxicity and
therapeutic ratio, but our recent clinical studies
have also shown that the pharmacokinetics of oral
CCNU in man exhibit additional differences from
those with either route in the mouse (Lee et al., In
press). What we can say is that MISO is able to act
either as a chemosensitizer or as a chemoprotector
depending on the nature of the alteration in CCNU
pharmacokinetics. Furthermore, we know that these
effects obtained with a relatively high dose MISO
are not exclusively mouse phenomena, since
equiactive doses of the more potent chemosensitizer
benznidazole are well tolerated in patients (Roberts
et al., in press) and do produce marked changes in
nitrosourea pharmacokinetics after oral CCNU
(Roberts et al., in preparation). We therefore
strongly recommend that the use of such regimes in
patients should be accompanied by detailed
pharmacokinetic investigations.
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